Moderna (MRNA, $151.89) beats Q4 earnings expectations
Moderna posted fourth quarter earnings that surpassed expectations. The pharma company also boosted its full-year revenue outlook for Covid vaccine sales.
and unveiled a new $3 billion share repurchase plan.
Moderna’s diluted GAAP earnings came in at $11.29 per share for the three months ending in December, beating the Street expectations of $9.90 per share. It incurred a loss of -69 cents per share loss in the year-ago quarter.
Revenues of $7.21 billion also exceeded analysts' estimates.
Looking ahead, the company projects sales of its mRNA-1273 coronavirus vaccine, Spikevax , in the region of $19 billion for the year 2022, with additional signed options of approximately $3 billion.
Moderna said that orders have also been confirmed for 2023 from Canada, the United Kingdom and Taiwan.
MRNA in upward trend: price expected to rise as it breaks its lower Bollinger Band on May 16, 2023
MRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where MRNA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MRNA's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MRNA just turned positive on May 22, 2023. Looking at past instances where MRNA's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 25, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In of 66 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for MRNA entered a downward trend on May 26, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.605) is normal, around the industry mean (24.864). P/E Ratio (10.989) is within average values for comparable stocks, (122.914). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.287). Dividend Yield (0.000) settles around the average of (0.030) among similar stocks. P/S Ratio (3.584) is also within normal values, averaging (303.544).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of transformative medicines for patients
Industry Biotechnology
MRNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRNA has been closely correlated with BNTX. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if MRNA jumps, then BNTX could also see price increases.
| Ticker / NAME | Correlation To MRNA | 1D Price Change % | ||
|---|---|---|---|---|
| MRNA | 100% | +2.10% | ||
| BNTX - MRNA | 76% Closely correlated | -0.87% | ||
| VIR - MRNA | 55% Loosely correlated | -0.38% | ||
| ARCT - MRNA | 49% Loosely correlated | -2.10% | ||
| ALNY - MRNA | 46% Loosely correlated | -0.96% | ||
| BEAM - MRNA | 45% Loosely correlated | -1.45% | ||
More | ||||
